Cubist gets priority review for new antibiotic; Adimab hits an antibody milestone;

@FierceBiotech: Bristol-Myers toes the next hep C frontier: a four-week cure. Story | Follow @FierceBiotech

@JohnCFierce: Man, that Burrill lawsuit makes for interesting reading. More | Follow @JohnCFierce

@DamianFierce: BIO2014 prediction: After a hall-of-fame career, "robust" classily gives way to promising rookie "disruptive." | Follow @DamianFierce

> Cubist ($CBST) secured the FDA's guarantee of a priority review for ceftolozane/tazobactam, an antibiotic for complicated urinary tract Infections and complicated intra-abdominal infections. News

> Antibody specialist Adimab notched its 50th discovery collaboration in 5 years through deals with Arsanis Biosciences, Merrimack Pharmaceuticals ($MACK) and Mersana Therapeutics. More

Medical Device News

@FierceMedDev: Covidien endovascular unit could be target for cuts after Medtronic merger. More | Follow @FierceMedDev

@StacyALawrence: How clinically useful is genome sequencing? Not very, yet. Story | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: "Smartcane" device uses bat-inspired sonar technology to improve independent mobility in the blind. Article | Follow @EmilyWFierce

> Medtronic's tax inversion scheme won't be all fun and games, experts say. More

> Danaher is a big question mark looming amid med tech M&A frenzy. Story

> Med tech outfits head to market with newly planned IPOs. Article

Pharma News

@FiercePharma:  Which pharma CEOs netted the biggest paychecks of 2013? Find out here. Story | Follow @FiercePharma

@TracyStaton: Trending now at FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. Report | Follow @EricPFierce

@CarlyHFierce: Top-read on FierceVaccines Thurs: Merck, Sanofi JV wins anal cancer indication for Gardasil in EU. Article | Follow @CarlyHFierce

> FDA moves for more warnings on testosterone products. Story

> Takeda taken to task for hiring so many 'foreigners.' More

> Why does Sovaldi cost $84,000? Gilead Sciences being pressed hard for an answer. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.